DOCSLIB.ORG

Part I Drugs and Preparations with Tariff Prices

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Part I Drugs and Preparations with Tariff Prices Part I Drugs And Preparations With Tariff Prices Part I Drugs And Preparations With Tariff Prices Special Container Item requiring reconstitution § Selected List Scheme (SLS) I Indicates an amendment Indicates price increase Indicates price decrease Category A Drugs which are readily available. Category C Drugs which are not readily available as a generic. Category M Drugs which are readily available. February 2013 1 Part I Drugs And Preparations With Tariff Prices Drug Quantity Basic Category Price Acacia spray dried powder 250 g 1524 C J M Loveridge Ltd Acamprosate 333mg gastro-resistant tablets 168 2880 C Campral EC Acarbose 100mg tablets 90 1287 A Acarbose 50mg tablets 90 700 A Acebutolol 100mg capsules 84 1497 C Sectral Acebutolol 200mg capsules 56 1918 C Sectral Acebutolol 400mg tablets 28 1792 A Aceclofenac 100mg tablets 60 941 A Acemetacin 60mg capsules 90 2820 C Emflex Acenocoumarol 1mg tablets 100 462 C Sinthrome Acetazolamide 250mg modified-release 30 1666 C Diamox SR capsules Acetazolamide 250mg tablets 112 2397 A Acetic acid 2% ear spray 5 ml 410 C EarCalm Acetic acid 33% liquid 500 ml 524 C Alliance Healthcare (Distribution) Ltd Acetone liquid 50 ml 66 A Aciclovir 200mg dispersible tablets 25 258 M Aciclovir 200mg tablets 25 270 M Aciclovir 200mg/5ml oral suspension sugar 125 ml 2927 A free Aciclovir 3% eye ointment 4.5 g 934 C Zovirax Aciclovir 400mg dispersible tablets 56 1164 A Aciclovir 400mg tablets 56 512 M Aciclovir 400mg/5ml oral suspension sugar 100 ml 3177 A free Aciclovir 5% cream 2 g 102 M 10 g 510 M Aciclovir 800mg dispersible tablets 35 1035 A Aciclovir 800mg tablets 35 600 M Acipimox 250mg capsules 90 4633 C Olbetam Adapalene 0.1% cream 45 g 1369 C Differin Adapalene 0.1% gel 45 g 1369 C Differin Adrenaline (base) 1mg/1ml (1 in 1,000) 10 406 A solution for injection ampoules Adrenaline (base) 500micrograms/0.5ml (1 in 10 1153 A 1,000) solution for injection ampoules Agomelatine 25mg tablets 28 3000 C Valdoxan Alclometasone 0.05% cream 50 g 268 C Modrasone Alendronic acid 10mg tablets 28 144 M Alendronic acid 70mg / Colecalciferol 4 2280 C Fosavance 70microgram tablets Alendronic acid 70mg tablets 4 79 M Alendronic acid 70mg/100ml oral solution unit 4 2280 C Rosemont dose sugar free Pharmaceuticals Ltd Alfacalcidol 1microgram capsules 30 921 M Alfacalcidol 250nanogram capsules 30 372 M Alfacalcidol 2micrograms/ml oral drops sugar 10 ml 2130 C One-Alpha free Alfacalcidol 500nanogram capsules 30 927 A Alfuzosin 10mg modified-release tablets 30 1251 C Alfuzosin 2.5mg tablets 60 670 M Alimemazine 10mg tablets 28 627 A Alimemazine 30mg/5ml oral solution 100 ml 4188 A Alimemazine 7.5mg/5ml oral solution 100 ml 1436 A Aliskiren 150mg tablets 28 2376 C Rasilez Aliskiren 300mg tablets 28 2856 C Rasilez Allopurinol 100mg tablets 28 100 M Allopurinol 300mg tablets 28 106 M Almond oil liquid 50 ml 69 C Thornton & Ross Ltd Almotriptan 12.5mg tablets 6 1814 C Almogran Alprostadil 10microgram powder and solvent 1 924 C Caverject for solution for injection vials February 2013 2 Part I Drugs And Preparations With Tariff Prices Alprostadil 1mg urethral sticks 1 1156 C Muse Alprostadil 20microgram powder and solvent 1 1194 C Caverject for solution for injection vials Alprostadil 250microgram urethral sticks 1 1130 C Muse Alprostadil 40microgram powder and solvent 1 2158 C Caverject for solution for injection vials Alprostadil 500microgram urethral sticks 1 1130 C Muse Alprostadil 5microgram powder and solvent for 1 773 C Caverject solution for injection vials Alum powder 500 g 487 C Alliance Healthcare (Distribution) Ltd Aluminium hydroxide 475mg capsules 120 914 C Alu-Cap Alverine 120mg capsules 60 1362 A Alverine 60mg capsules 100 1133 A Amantadine 100mg capsules 56 990 C Symmetrel Amantadine 50mg/5ml oral solution sugar free 150 ml 533 C Symmetrel Syrup Amiloride 2.5mg / Cyclopenthiazide 28 324 C Navispare 250microgram tablets Amiloride 5mg / Bumetanide 1mg tablets 28 3099 A Amiloride 5mg tablets 28 98 M Aminophylline 250mg/10ml solution for 10 654 A injection ampoules Amiodarone 100mg tablets 28 150 M Amiodarone 200mg tablets 28 201 M Amisulpride 100mg tablets 60 657 M Amisulpride 100mg/ml oral solution sugar free 60 ml 3309 A Amisulpride 200mg tablets 60 1030 M Amisulpride 400mg tablets 60 8122 A Amisulpride 50mg tablets 60 388 M Amitriptyline 10mg tablets 28 73 M Amitriptyline 25mg tablets 28 74 M Amitriptyline 25mg/5ml oral solution sugar free 150 ml 1722 A Amitriptyline 50mg tablets 28 82 M Amitriptyline 50mg/5ml oral solution sugar free 150 ml 1833 A Amlodipine 10mg / Valsartan 160mg tablets 28 2209 C Exforge Amlodipine 10mg tablets 28 94 M Amlodipine 5mg / Valsartan 160mg tablets 28 2209 C Exforge Amlodipine 5mg / Valsartan 80mg tablets 28 1676 C Exforge Amlodipine 5mg tablets 28 87 M Ammonia and Ipecacuanha mixture 200 ml 129 C Thornton & Ross Ltd Ammonia solution aromatic 500 ml 809 C J M Loveridge Ltd Ammonium bicarbonate powder 500 g 364 C J M Loveridge Ltd Amorolfine 5% medicated nail lacquer 5 ml 1135 C Loceryl Lacquer Amoxicillin 125mg/1.25ml oral suspension 20 ml 318 C Amoxil paediatric Amoxicillin 125mg/5ml oral suspension 100 ml 106 M Amoxicillin 125mg/5ml oral suspension sugar 100 ml 115 M free Amoxicillin 1g powder for solution for injection 10 1096 C Amoxil vials Amoxicillin 250mg capsules 15 88 M 21 123 M Amoxicillin 250mg/5ml oral suspension 100 ml 120 M Amoxicillin 250mg/5ml oral suspension sugar 100 ml 142 M free Amoxicillin 3g oral powder sachets sugar free 2 919 A Amoxicillin 500mg capsules 15 106 M 21 148 M Amoxicillin 500mg powder for solution for 10 548 C Amoxil injection vials Ampicillin 125mg/5ml oral suspension 100 ml 788 A Ampicillin 250mg capsules 28 513 A Ampicillin 250mg/5ml oral suspension 100 ml 1184 A Ampicillin 500mg capsules 28 2312 A Anastrozole 1mg tablets 28 194 M February 2013 3 Part I Drugs And Preparations With Tariff Prices Anise oil liquid 100 ml 929 C J M Loveridge Ltd Anise water concentrated 100 ml 1037 A Antazoline 0.5% / Xylometazoline 0.05% eye 10 ml 235 C Otrivine-Antistin drops Apraclonidine 5mg/ml eye drops 5 ml 1088 C Iopidine Aqueous cream 100 g 104 M 500 g 520 M Arachis oil liquid 200 ml 329 A Aripiprazole 10mg tablets 28 9604 C Abilify Aripiprazole 15mg tablets 28 9604 C Abilify Aripiprazole 30mg tablets 28 19208 C Abilify Aripiprazole 5mg tablets 28 9604 C Abilify Ascorbic acid 100mg tablets 28 103 A Ascorbic acid 200mg tablets 28 123 A Ascorbic acid 500mg tablets 28 251 A Ascorbic acid 50mg tablets 28 127 A Ascorbic acid powder 100 g 449 A Asenapine 10mg sublingual tablets sugar free 60 10260 C Sycrest Asenapine 5mg sublingual tablets sugar free 60 10260 C Sycrest Aspirin 300mg dispersible tablets 32 128 M 100 400 M Aspirin 300mg gastro-resistant tablets 100 1189 A Aspirin 300mg tablets 32 223 A Aspirin 75mg dispersible tablets 28 69 M 100 246 M Aspirin 75mg gastro-resistant tablets 28 77 M Aspirin 75mg tablets 28 82 C Alissa Healthcare Research Ltd Aspirin 900mg / Metoclopramide 10mg oral 6 661 C Migramax powder sachets sugar free Aspirin powder 250 g 774 C J M Loveridge Ltd Atenolol 100mg tablets 28 77 M Atenolol 25mg tablets 28 71 M Atenolol 25mg/5ml oral solution sugar free 300 ml 603 A Atenolol 50mg tablets 28 72 M Atomoxetine 10mg capsules 28 6246 C Strattera Atomoxetine 18mg capsules 28 6246 C Strattera Atomoxetine 25mg capsules 28 6246 C Strattera Atomoxetine 40mg capsules 28 6246 C Strattera Atomoxetine 60mg capsules 28 6246 C Strattera Atorvastatin 10mg chewable tablets sugar free 30 1380 C Lipitor Atorvastatin 10mg tablets 28 130 M Atorvastatin 20mg chewable tablets sugar free 30 2640 C Lipitor Atorvastatin 20mg tablets 28 176 M Atorvastatin 40mg tablets 28 199 M Atorvastatin 80mg tablets 28 373 M Atropine 1% eye drops 10 ml 950 C Martindale Pharmaceuticals Ltd Atropine 1% eye drops 0.5ml unit dose 20 1377 C Minims preservative free Atropine 600microgram tablets 28 2380 A Atropine 600micrograms/1ml solution for 10 432 A injection ampoules Azathioprine 25mg tablets 28 441 M Azathioprine 50mg tablets 56 436 M Azelaic acid 15% gel 30 g 748 C Finacea Azelaic acid 20% cream 30 g 374 C Skinoren Azelastine 140micrograms/dose nasal spray 22 ml 1048 C Rhinolast Azilsartan medoxomil 20mg tablets 28 1680 C Edarbi Azilsartan medoxomil 40mg tablets 28 1680 C Edarbi Azilsartan medoxomil 80mg tablets 28 1995 C Edarbi Azithromycin 15mg/g eye drops 0.25g unit 6 699 C Azyter dose preservative free Azithromycin 200mg/5ml oral suspension 15 ml 406 C Zithromax 22.5 ml 610 C Zithromax February 2013 4 Part I Drugs And Preparations With Tariff Prices 30 ml 1104 C Zithromax Azithromycin 250mg capsules 6 1394 A Azithromycin 250mg tablets 4 339 M Azithromycin 500mg tablets 3 234 M Drug Quantity Basic Category Price Baclofen 10mg tablets 84 188 M Baclofen 5mg/5ml oral solution sugar free 300 ml 601 M Balsalazide 750mg capsules 130 3042 C Colazide Bambuterol 10mg tablets 28 1446 C Bambec Bambuterol 20mg tablets 28 1577 C Bambec Beclometasone 100micrograms/dose / 120 dose 2932 C Fostair Formoterol 6micrograms/dose inhaler CFC free Beclometasone 100micrograms/dose breath 200 dose 1721 C Qvar Autohaler actuated inhaler CFC free Beclometasone 250micrograms/dose dry powder 100 dose 1231 C Asmabec 250 inhaler Clickhaler Beclometasone 50micrograms/dose breath 200 dose 787 C Qvar Autohaler actuated inhaler CFC free Beclometasone 50micrograms/dose nasal spray 200 dose 235 M Beeswax white solid 500 g 580 C J M Loveridge Ltd Beeswax yellow solid 500 g 580 C J M Loveridge Ltd Bendroflumethiazide 2.5mg / Potassium chloride 100 899 C Neo-Naclex-K 630mg (potassium 8.4mmol)
Load more

Recommended publications
  • Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More Information
    Cambridge University Press 978-0-521-86781-8 - Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More information Index Abdominal distension in lung elastance oxygen toxicity 270 incidence data 240 345, 346 patient assessment 118, 115–119, 120 laryngeal injuries 248, 247–248 Abdominal paradox 27 recruitment manoeuvres 118–119, left ventricular performance 273 N-Acetylcysteine 79–80, 81, 357, 358 131, 219 lorazepam 165 Acinetobacter baumanii, SDD for 260 trials (See ARDS net trials) lung injury, ventilator-associated (See Acute hypoxaemic respiratory failure ventilation management Lung injury, defined 115 HFOV 127–131, 305–306 ventilator-associated) Acute lung injury (ALI) IRV 125–126 maxillary sinusitis/middle ear blast injuries 212 liquid 228 effusions 246–247 hypoxaemia, PEEP management of modes 215–216 midazolam 165 124–125 overview 214 nasopharyngeal airways 243–245, infants/children 300–301 principles 214–215, 216 246–247 liquid ventilation 228 Acute respiratory failure (ARF) nasotracheal intubation 315 patient assessment 118, 115–119, clinical presentation 29 neurological function 277, 276–277, 120, 197 mechanisms of 24 278, 280 recruitment manoeuvres 131, 219 NIV 43, 49–50 (See also Non-invasive NMBAs 171, 176–177, 276–280 ventilation management ventilation (NIV)) NSAIDs 181 HFV 149–150 overview 24, 22–24, 25, 142 opioid agonists 180 IRV 125–126 Adaptive support ventilation® 113, 361 opioids 276–280 modes 215–216 Adrenaline 81 overview 21, 239, 241 overview 214 Adrenergic receptor antagonists 349, oxygen toxicity
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • Automation List – 1St December 2011
    st Automation List – 1 December 2011 Abidec Drops Packsize 25 Adcal D3 Chewable Tabs Packsize 56 Abilify Tabs 10 Mg Packsize 28 Adcal D3 Chewable Tabs Packsize 56 Abstral Tabs 100 Micrograms Packsize 10 Adcal D3 Dissolve Effervescent Tabs Packsize 56 Abstral Tabs 100 Micrograms Packsize 30 Adcal D3 Tabs Packsize 112 Abstral Tabs 200 Micrograms Packsize 10 Adefovir Dipivoxil Tabs 10 Mg Packsize 30 Abstral Tabs 200 Micrograms Packsize 30 Adenuric Tabs 80 Mg Packsize 28 Abstral Tabs 300 Micrograms Packsize 10 Adipine 10 Mr 10 Mg Tabs Packsize 56 Abstral Tabs 300 Micrograms Packsize 30 Adipine 20 Mr 20 Mg Tabs Packsize 56 Abstral Tabs 400 Micrograms Packsize 10 Adipine 30 Xl Tabs 30 Mg Packsize 28 Abstral Tabs 400 Micrograms Packsize 30 Adipine 60 Xl Tabs 60 Mg Packsize 28 Abstral Tabs 600 Micrograms Packsize 30 Adizem Sr 120 Mg Caps Packsize 56 Acamprosate Calcium 333 Mg Ec Tabs Packsize 168 Adizem Sr 180 Mg Caps Packsize 56 Acarbose Tabs 100 Mg Packsize 90 Adizem Sr 90 Mg Caps Packsize 56 Acarbose Tabs 50 Mg Packsize 90 Adizem Sr Tabs 120 Mg Packsize 56 Accolate Tabs 20 Mg Packsize 56 Adizem Xl 120 Mg Caps Packsize 28 Accupro Tabs 10 Mg Packsize 28 Adizem Xl 180 Mg Caps Packsize 28 Accupro Tabs 20 Mg Packsize 28 Adizem Xl 200 Mg Caps Packsize 28 Accupro Tabs 40 Mg Packsize 28 Adizem Xl 240 Mg Caps Packsize 28 Accupro Tabs 5 Mg Packsize 28 Adizem Xl 300 Mg Caps Packsize 28 Accuretic Tabs Packsize 28 Adoport Caps 1 Mg Packsize 100 Acebutolol Caps 100 Mg Packsize 84 Adoport Caps 1 Mg Packsize 50 Acebutolol Caps 200 Mg Packsize 56 Adoport Caps
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]
  • Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013
    Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine, Pyrimidine, Azaindole, Quinoline, Thiazole, Isatin, Phenanthrene, Thiophene We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Product Name and Description 26988-72-7 1-METHYL-DL-TRYPTOPHAN 68886-07-7 2-Fluoro-4-hydroxyphenylaceticacid 72607-53-5 N-(3-AMINOPROPYL)METHACRYLAMIDE 171049-41-5 7-AMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLICACIDTERT- BUTYLESTER 885280-38-6 (3-OXO-CYCLOHEXYL)-CARBAMICACIDTERT-BUTYLESTER 186826-86-8 MOXIFLOXACIN HCL 102735-53-5 L-CYCLOPROPYLALANINE 145100-50-1 2-[N,N-BIS(TRIFLUOROMETHYLSULFONYL)AMINO]PYRIDINE 143491-57-0 Emtricitabine 39809-25-1 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one 147127-20-6 Tenofovir 716-39-2 2,3-NAPHTHALENEDICARBOXYLICANHYDRIDE 4333-62-4 1,3-DIMETHYLIMIDAZOLIUMIODIDE 108-45-2 m-Phenylenediamine 1961-72-4 R-(3)-HYDROXYMYRISTICACID 131-48-6 N-Acetylneuraminicacid 88196-70-7 (R)-1-(3-Methoxyphenyl)ethylamine 680-31-9 Hexamethylphosphoramide 486-66-8 Daidzein 872-50-4 1-Methyl-2-pyrrolidinone 425378-68-3 2-FLUORO-5-NITROPHENYLBORONICACIDPINACOLESTER 115651-29-1 5-ACETYL-2-AMINO-4-HYDROXYBENZOICACID 115269-99-3 N,N-BIS-BOC-N-ALLYLAMINE
    [Show full text]
  • Pharmaceutical Compoundingand Dispensing, Second
    Pharmaceutical Compounding and Dispensing Pharmaceutical Compounding and Dispensing SECOND EDITION John F Marriott BSc, PhD, MRPharmS, FHEA Professor of Clinical Pharmacy Aston University School of Pharmacy, UK Keith A Wilson BSc, PhD, FRPharmS Head of School Aston University School of Pharmacy, UK Christopher A Langley BSc, PhD, MRPharmS, MRSC, FHEA Senior Lecturer in Pharmacy Practice Aston University School of Pharmacy, UK Dawn Belcher BPharm, MRPharmS, FHEA Teaching Fellow, Pharmacy Practice Aston University School of Pharmacy, UK Published by the Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN, UK 1559 St Paul Avenue, Gurnee, IL 60031, USA Ó Pharmaceutical Press 2010 is a trade mark of Pharmaceutical Press Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society of Great Britain First edition published 2006 Second edition published 2010 Typeset by Thomson Digital, Noida, India Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 912 5 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of John F Marriott, Keith A Wilson, Christopher A Langley and Dawn Belcher to be identified as the author of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • European Patent Office
    Europäisches Patentamt *EP001021204B1* (19) European Patent Office Office européen des brevets (11) EP 1 021 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 47/32, A61L 25/00 of the grant of the patent: 28.12.2005 Bulletin 2005/52 (86) International application number: PCT/US1998/020091 (21) Application number: 98949505.6 (87) International publication number: (22) Date of filing: 25.09.1998 WO 1999/015210 (01.04.1999 Gazette 1999/13) (54) BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS BIOLOGISCHE KLEBER UND VERFAHREN ZUR TOPISCHEN VERABREICHUNG VON WIRKSTOFFEN COMPOSITIONS BIOADHESIVES ET METHODES D’ADMINISTRATION LOCALE D’AGENTS ACTIFS (84) Designated Contracting States: • HOUZE, David AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Miami, FL 33186 (US) MC NL PT SE • KANIOS, David Miami, FL 33196 (US) (30) Priority: 26.09.1997 US 61155 P (74) Representative: Isenbruck, Günter (43) Date of publication of application: Isenbruck, Bösl, Hörschler, Wichmann, Huhn 26.07.2000 Bulletin 2000/30 Patentanwälte Theodor-Heuss-Anlage 12 (73) Proprietor: NOVEN PHARMACEUTICALS, INC. 68165 Mannheim (DE) Miami, FL 33186 (US) (56) References cited: (72) Inventors: FR-A- 2 532 546 GB-A- 1 050 070 • MANTELLE, Juan GB-A- 2 046 773 US-A- 4 593 053 Miami, FL 33176 (US) US-A- 5 656 286 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Electronic Supplementary Material
    Supplementary material Thorax Electronic Supplementary Material Contents: MEDLINE search strategy: ........................................................................................................ 1 Number of search results according to data source: .................................................................. 4 Inclusion/Exclusion criteria of eligible trials: ............................................................................ 5 List of excluded studies after full text review: ......................................................................... 14 Reporting of adverse events and development of other pathologies: ...................................... 19 Deviations between this review and protocol: ......................................................................... 20 Funnel Plots: ............................................................................................................................ 20 Explanation for observed Risk of Bias differences for included trials between this review and Tarrant 2019 review: ................................................................................................................ 24 MEDLINE search strategy: Search was adapted appropriately for other databases. Condition: 1. Acute hypoxic respiratory failure 2. Acute hypoxemic respiratory failure 3. Acute hypoxaemic respiratory failure 4. Acute hypercapnic respiratory failure 5. AHRF 6. Respiratory Distress Syndrome, Adult/ 7. Acute respiratory failure 8. ARF 9. Severe hypoxic respiratory failure 10. Severe
    [Show full text]